WCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder

Simple item page
dc.contributor.authorStein D.J.
dc.contributor.authorBandelow B.
dc.contributor.authorHollander E.
dc.contributor.authorNutt D.J.
dc.contributor.authorOkasha A.
dc.contributor.authorPollack M.H.
dc.contributor.authorSwinson R.P.
dc.contributor.authorZohar J.
dc.date.accessioned2011-05-15T16:01:25Z
dc.date.available2011-05-15T16:01:25Z
dc.date.issued2003
dc.description.abstractPosttraumatic stress disorder (PTSD) is a common and disabling condition. In addition to combat-related PTSD, the disorder occurs in civilians exposed to severe traumatic events, with the community prevalence rate for the combined populations reaching as high as 12%. If left untreated, PTSD may continue for years after the stressor event, resulting in severe functional and emotional impairment and a dramatic reduction in quality of life, with negative economic consequences for both the sufferer and society as a whole. Although PTSD is often overlooked, diagnosis is relatively straight-forward once a triggering stressor event and the triad of persistent symptoms-reexperiencing the traumatic event, avoiding stimuli associated with the trauma, and hyperarousal-have been identified. However, comorbid conditions of anxiety and depression frequently hamper accurate diagnosis. Treatment for PTSD includes psychotherapy and pharmacotherapy. The latter includes selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors. Only SSRIs have been proven effective and safe in long-term randomized controlled trials. Current guidelines from the Expert Consensus Panel for PTSD recommend treatment of chronic PTSD for a minimum of 12-24 months.
dc.description.versionConference Paper
dc.identifier.citationCNS Spectrums
dc.identifier.citation8
dc.identifier.citation8 SUPPL. 1
dc.identifier.issn10928529
dc.identifier.urihttp://hdl.handle.net/10019.1/11965
dc.subjectamitriptyline
dc.subjectbenzodiazepine derivative
dc.subjectbrofaromine
dc.subjectbuspirone
dc.subjectcarbamazepine
dc.subjectcitalopram
dc.subjectfluoxetine
dc.subjectfluvoxamine
dc.subjectimipramine
dc.subjectlamotrigine
dc.subjectmonoamine oxidase inhibitor
dc.subjectnefazodone
dc.subjectnoradrenalin uptake inhibitor
dc.subjectparoxetine
dc.subjectphenelzine
dc.subjectserotonin noradrenalin reuptake inhibitor
dc.subjectserotonin uptake inhibitor
dc.subjectsertraline
dc.subjecttricyclic antidepressant agent
dc.subjectunclassified drug
dc.subjectvalproic acid
dc.subjectanxiety
dc.subjectbehavior therapy
dc.subjectclinical feature
dc.subjectclinical trial
dc.subjectcognitive therapy
dc.subjectcombat related posttraumatic stress disorder
dc.subjectcomorbidity
dc.subjectconference paper
dc.subjectdepression
dc.subjectdisease course
dc.subjectdrug efficacy
dc.subjectexposure therapy
dc.subjecthealth economics
dc.subjecthuman
dc.subjectinsomnia
dc.subjectinternational cooperation
dc.subjectlong term care
dc.subjectneuropathology
dc.subjectposttraumatic stress disorder
dc.subjectpractice guideline
dc.subjectprevalence
dc.subjectpriority journal
dc.subjectpsychopharmacotherapy
dc.subjectpsychotherapy
dc.subjectpsychotrauma
dc.subjectquality of life
dc.subjectrecurrent disease
dc.subjectrelaxation training
dc.subjectside effect
dc.subjectsymptomatology
dc.subjectwar
dc.subjectWorld Council of Anxiety
dc.subjectdifferential diagnosis
dc.subjectmethodology
dc.subjectmultimodality cancer therapy
dc.subjectreview
dc.subjecttime
dc.subjectAntidepressive Agents, Tricyclic
dc.subjectCognitive Therapy
dc.subjectCombined Modality Therapy
dc.subjectDiagnosis, Differential
dc.subjectHumans
dc.subjectMonoamine Oxidase Inhibitors
dc.subjectSerotonin Uptake Inhibitors
dc.subjectStress Disorders, Post-Traumatic
dc.subjectTime Factors
dc.titleWCA Recommendations for the Long-Term Treatment of Posttraumatic Stress Disorder
dc.typeConference Paper
Files
Collections
Stellenbosch University - Scopus Publications